Product Name: CAMK4 (197-203) pT200
Product Number: PE-04AJC90
Size: | 200 µg | | Price: | 37.00 |
| 1 mg | | $US | 74.00 |
| 5 mg | | | 174.00 |
Peptide Name: CAMK4 (197-203) pT200
Product Use: Services as a blocking peptide for use with the CaMK4-pT200 rabbit polyclonal antibody (Cat. No.: AB-PK556) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain. T200 phosphorylation stimulates phosphotransferase activity and regulates transcription.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LMK-pT-VCG
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Scientific Background: CaMK4 is a protein-serine/threonine kinase of the CAMK group and CAMK1 family. It is a calcium/calmodulin-dependent protein kinase. This kinase is monomeric in structure and occurs in two isoforms generated by alternative splcing from the same gene. It is implicated in immune response, inflammation, memory consolidation, positive selection of T lymphocytes, cytokine production, regulation in neurons and male germ cells, survival and differentiation of osteoblasts and dendritic cells. It is highly expressed in rat tissues such as the forebrain, lymphocytes, spleen, testis, and thymus. Immunohistochemical studies have demonstrated a nuclear localization of the transiently expressed CaMK4. The cytoskeletal and perinuclear localization of inducible CaMK4 implies that the kinase may be a modulator of cell shape and/or motility and/or activity of a cytoskeleton-associated nuclear factor. It regulates many transcription activators such as CREB1, and JUN. It can also activate MAPK pathway through phosphorylation of ELK1 and ATF2. Mutations (S12A, S13A, T57A+K58E, K75E, T200A) are mostly result in loss of phosphotransferase activity or loss of activation by the upstream kinases CaMKK1 or CaMKK2. Some mutations (S189A, H309D+M310E+T312D+F320D+N321D+) lead to a constitutively active form.